Analysts predict that Ignyta, Inc. (NASDAQ:RXDX) will announce earnings per share of ($0.44) for the current quarter, Zacks reports. Zero analysts have made estimates for Ignyta’s earnings, with the highest EPS estimate coming in at ($0.43) and the lowest estimate coming in at ($0.46). Ignyta reported earnings per share of ($0.67) during the same quarter last year, which would suggest a positive year-over-year growth rate of 34.3%. The business is expected to report its next earnings report on Tuesday, March 13th.

According to Zacks, analysts expect that Ignyta will report full-year earnings of ($2.27) per share for the current year, with EPS estimates ranging from ($2.41) to ($2.13). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.09) per share, with EPS estimates ranging from ($2.65) to ($1.81). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Ignyta.

Ignyta (NASDAQ:RXDX) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.03.

RXDX has been the subject of several recent analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $15.00 target price on shares of Ignyta in a report on Wednesday, September 27th. J P Morgan Chase & Co reaffirmed a “buy” rating and issued a $20.00 target price (up previously from $18.00) on shares of Ignyta in a report on Thursday, October 12th. Zacks Investment Research downgraded shares of Ignyta from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. SunTrust Banks initiated coverage on shares of Ignyta in a report on Monday, November 20th. They issued a “buy” rating for the company. Finally, Ladenburg Thalmann Financial Services upped their target price on shares of Ignyta from $20.25 to $31.00 in a report on Wednesday, October 18th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.80.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tang Capital Management LLC boosted its holdings in shares of Ignyta by 19.9% during the 2nd quarter. Tang Capital Management LLC now owns 4,763,602 shares of the biopharmaceutical company’s stock valued at $49,303,000 after purchasing an additional 790,802 shares during the last quarter. RA Capital Management LLC boosted its holdings in shares of Ignyta by 291.8% during the 2nd quarter. RA Capital Management LLC now owns 4,016,990 shares of the biopharmaceutical company’s stock valued at $41,576,000 after purchasing an additional 2,991,699 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Ignyta by 29.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,638,632 shares of the biopharmaceutical company’s stock valued at $37,660,000 after purchasing an additional 833,798 shares during the last quarter. Broadfin Capital LLC boosted its holdings in shares of Ignyta by 11.5% during the 2nd quarter. Broadfin Capital LLC now owns 2,941,247 shares of the biopharmaceutical company’s stock valued at $30,442,000 after purchasing an additional 303,901 shares during the last quarter. Finally, Frazier Management LLC boosted its holdings in shares of Ignyta by 123.2% during the 2nd quarter. Frazier Management LLC now owns 2,173,593 shares of the biopharmaceutical company’s stock valued at $22,497,000 after purchasing an additional 1,199,900 shares during the last quarter. 72.88% of the stock is owned by institutional investors and hedge funds.

Shares of Ignyta (NASDAQ:RXDX) traded down $0.30 during mid-day trading on Thursday, hitting $15.25. 2,370,000 shares of the stock were exchanged, compared to its average volume of 895,534. Ignyta has a 12-month low of $4.60 and a 12-month high of $18.30. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.34.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/brokerages-expect-ignyta-inc-rxdx-to-announce-0-44-earnings-per-share/1770336.html.

About Ignyta

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Get a free copy of the Zacks research report on Ignyta (RXDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ignyta (NASDAQ:RXDX)

Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.